Neurent Medical is a med-tech company focused on transforming care for chronic inflammatory sinonasal diseases, beginning with chronic rhinitis. Its flagship NEUROMARK System employs proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, providing durable symptom relief with minimal downtime. The company positions the platform as a differentiated, clinician-friendly alternative that tackles the root cause of rhinitis rather than merely managing symptoms. Headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts, Neurent Medical is expanding commercial availability and building further clinical evidence to support adoption. The newly secured capital will accelerate market penetration, support additional clinical studies across broader populations, and fund development of future indication and product pipeline extensions. The firm has attracted prominent medtech investors and added new board members to guide this next growth phase. No revenue or user metrics were disclosed in the article, but leadership emphasizes scaling sales and broadening evidence as immediate priorities.

Total raised

$110M

Funding rounds

3

Latest round

Series C

Latest activity

Feb 2026